Trials / Completed
CompletedNCT00712933
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 738 (actual)
- Sponsor
- Human Genome Sciences Inc., a GSK Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a long-term continuation study to provide continuing treatment to subjects with SLE.
Detailed description
This trial is a long-term continuation study to provide continuing treatment to subjects with System Lupus Erythematosus (SLE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | belimumab | Recombinant, fully human, monoclonal antibody Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days. |
Timeline
- Start date
- 2008-05-30
- Primary completion
- 2016-12-09
- Completion
- 2016-12-09
- First posted
- 2008-07-10
- Last updated
- 2019-12-05
- Results posted
- 2018-01-16
Locations
110 sites across 28 countries: Argentina, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, France, Germany, Hong Kong, India, Israel, Italy, Mexico, Netherlands, Peru, Philippines, Poland, Puerto Rico, Romania, Russia, Slovakia, South Korea, Spain, Sweden, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00712933. Inclusion in this directory is not an endorsement.